Results 271 to 280 of about 470,131 (305)
Some of the next articles are maybe not open access.
Minimal residual disease in gastrointestinal cancer
Seminars in Surgical Oncology, 2001AbstractTumor progression after curative resection of gastrointestinal carcinomas is probably caused by pre‐ or intraoperative tumor cell dissemination. Disseminated tumor cells are generally detected by immunohistochemistry‐ or PCR‐based molecular‐biology methods. A consensus on which is the most adequate detection method has not yet been found, which
P, Kienle, M, Koch
openaire +2 more sources
Minimal Residual Disease in Leukemia in Children
Annals of the New York Academy of Sciences, 1997Many chromosomal translocations involved in leukemia have been defined at the molecular level in recent years. In addition to advancing the understanding of pathological mechanisms underlying the transformation process, the cloning and sequencing of the genes altered by the translocations have provided new tools for diagnosis and monitoring of patients.
B, Kornhuber +3 more
openaire +2 more sources
Advances in the detection of minimal residual disease
Current Opinion in Hematology, 1997The study of minimal residual disease (MRD) is an attempt to detect and define the significance of leukemia invisible to normal morphologic examination. In many circumstances the clinical significance of MRD detection is unclear, because the technical ability to detect and quantify it has outpaced studies demonstrating its clinical significance.
J, Radich, B, Thomson
openaire +2 more sources
2009
During the past 30 years, survival rates after allogeneic stem cell transplantation (SCT) have been improved substantially. These improvements have mostly been due to better graft matching using genomic HLA typing, GVHD prophylaxis, infection management, and supportive care [1-3]. The incidence of leukemia relapse and death rates after relapse, however,
openaire +1 more source
During the past 30 years, survival rates after allogeneic stem cell transplantation (SCT) have been improved substantially. These improvements have mostly been due to better graft matching using genomic HLA typing, GVHD prophylaxis, infection management, and supportive care [1-3]. The incidence of leukemia relapse and death rates after relapse, however,
openaire +1 more source
Minimal Residual Disease in Breast Cancer
Cancer and Metastasis Reviews, 1999The incidence of breast cancer is increasing dramatically in the developed countries. Although attention is being paid to diagnose breast cancer early through screening programs, still a significant number of patients classified to have a localised disease at diagnosis, later experience a systemic recurrence.
G, Kvalheim, B, Naume, J M, Nesland
openaire +2 more sources
Detection of minimal residual disease in ALL
1993Complete remission (CR) of acute leukemia is defined in clinical practice as the presence in the bone marrow of less than 5% blast cells, a level determined by the limits of reliable detection by morphology. Mathematical models predict that the level of residual disease during clinical remission could vary from 1010 leukemic cells following early ...
M, Deane, A V, Hoffbrand
openaire +2 more sources
Minimal Residual Disease in Gastric Cancer
2003In curatively resected gastric cancer, the incidence of distant relapse is as high as 30%. Although the most important factor contributing to the local control of the tumor is the microscopic tumor-free margin of the surgical resection, the occurrence of distant metastases is in many cases due to preoperative or perioperative tumor cell dissemination ...
Hendrik, Seeliger +2 more
openaire +2 more sources
Minimal Residual Disease in Prostate Cancer
2018Detection of minimal residual disease (MRD) in prostate cancer over several decades has greatly informed our understanding of dissemination and recurrence, but has not yet been routinely used in clinical care. Investigators have detected MRD by identification of prostate cancer cells in the bone marrow; termed disseminated tumor cells (DTCs) and blood;
Frank C, Cackowski, Russell S, Taichman
openaire +2 more sources
Minimal residual disease in multiple myeloma
La Presse MédicaleMinimal Residual Disease (MRD) in multiple myeloma has emerged as a significant prognostic factor, guiding treatment strategies and enhancing patient outcomes. Despite advancements in therapies such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR-T cell therapy, and bispecific antibodies, complete eradication of malignant ...
Nour, Moukalled +3 more
openaire +2 more sources
Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
Hematology/Oncology Clinics of North America, 2021Othman Al-Sawaf +2 more
exaly